Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dermal features derived from optoacoustic tomograms via machine learning correlate microangiopathy phenotypes with diabetes stage.
Karlas A, Katsouli N, Fasoula NA, Bariotakis M, Chlis NK, Omar M, He H, Iakovakis D, Schäffer C, Kallmayer M, Füchtenbusch M, Ziegler A, Eckstein HH, Hadjileontiadis L, Ntziachristos V. Karlas A, et al. Among authors: fuchtenbusch m. Nat Biomed Eng. 2023 Dec;7(12):1667-1682. doi: 10.1038/s41551-023-01151-w. Epub 2023 Dec 4. Nat Biomed Eng. 2023. PMID: 38049470 Free PMC article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, Sapin H, Barrett A, Guerci B, Giorgino F, Füchtenbusch M, García-Pérez LE. Boye KS, et al. Among authors: fuchtenbusch m. Diabetes Obes Metab. 2023 Dec;25(12):3453-3464. doi: 10.1111/dom.15145. Epub 2023 Sep 15. Diabetes Obes Metab. 2023. PMID: 37712754
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Giorgino F, Guerci B, Füchtenbusch M, Lebrec J, Boye K, Orsini Federici M, Heitmann E, Dib A, Yu M, Sapin H, García-Pérez LE. Giorgino F, et al. Among authors: fuchtenbusch m. Diabetes Obes Metab. 2023 Dec;25(12):3465-3477. doi: 10.1111/dom.15244. Epub 2023 Sep 12. Diabetes Obes Metab. 2023. PMID: 37700627
Therapy for Type 1 Diabetes.
Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Uebel T, Droßel D. Haak T, et al. Among authors: fuchtenbusch m. Exp Clin Endocrinol Diabetes. 2024 Mar;132(3):125-135. doi: 10.1055/a-2166-6695. Epub 2024 Feb 16. Exp Clin Endocrinol Diabetes. 2024. PMID: 38365208 English. No abstract available.
Diabetes and Pregnancy.
Hummel M, Füchtenbusch M, Battefeld W, Bührer C, Groten T, Haak T, Kainer F, Kautzky-Willer A, Lechner A, Meissner T, Nagel-Reuper C, Schäfer-Graf U, Siegmund T. Hummel M, et al. Among authors: fuchtenbusch m. Exp Clin Endocrinol Diabetes. 2023 Feb;131(1-02):4-12. doi: 10.1055/a-1946-3648. Epub 2023 Jan 10. Exp Clin Endocrinol Diabetes. 2023. PMID: 36626920 No abstract available.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B, Giorgino F, Sapin H, Boye K, Lebrec J, Federici MO, Heitmann E, Dib A, Füchtenbusch M, García-Pérez LE. Guerci B, et al. Among authors: fuchtenbusch m. Diabetes Obes Metab. 2022 Dec;24(12):2373-2382. doi: 10.1111/dom.14823. Epub 2022 Aug 31. Diabetes Obes Metab. 2022. PMID: 35876235 Free PMC article.
Therapy of Type 1 Diabetes.
Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Uebel T, Droßel D. Haak T, et al. Among authors: fuchtenbusch m. Exp Clin Endocrinol Diabetes. 2022 Sep;130(S 01):S39-S48. doi: 10.1055/a-1624-3340. Epub 2022 Apr 1. Exp Clin Endocrinol Diabetes. 2022. PMID: 35373309 No abstract available.
49 results